Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Key Points

• To evaluate the efficacy of panitumumab in improving progression-free survival in patients with chemotherapy-refractory metastatic colorectal cancer.
• Open-label phase III trial comparing panitumumab plus best supportive care to best supportive care alone.
• Patient population consisted of those with chemotherapy-refractory metastatic colorectal cancer.
• Evaluated toxicity and efficacy of panitumumab.
• Panitumumab significantly improved progression-free survival compared to best supportive care alone.
• Toxicity was manageable, indicating that panitumumab may be a viable treatment option.